AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

In terms of PFS, the way this study is powered ... how do you foresee the competitive landscape for third-line DLBCL evolving in 2025 and beyond? And how might that differ from '24?

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma ... free survival (PFS), with overall survival ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

We excluded patients with histologic transformation to diffuse large B-cell lymphoma or other aggressive lymphomas at ... Real-world progression-free survival (Rw-PFS) is defined as the time from ...

Future Oncol. 2013;9(3):355-368. While preliminary clinical data are encouraging, the durability of responses observed with treatment with ADC-based regimens remains to be determined. Equally ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

Additionally, the median PFS was 4.8 months (95% CI ... discussed what the findings from the primary analysis of the ELM-1 trial of odronextamab in DLBCL means for oncologists. Matasar: We have long ...

Multivariate analysis revealed that serum CA125, cell of origin, IPI score and albumin were independent prognostic factors for OS and PFS. In addition, the results of the immunohistochemistry ...